FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript

Page 6 of 6

Paul Choi: Great. Thank you.

Operator: I am showing no further questions at this time. I would now like to turn the conference back over to Thane Wettig for closing remarks.

Thane Wettig: Thank you. So we really appreciate your participation in today’s investor call and your interest in FibroGen. We believe we have a really exciting future ahead of us with the pamrevlumab readouts with a robust and growing roxadustat business, with an exciting early-stage pipeline and a really strong balance sheet. And so, we look forward to maintaining the engagement and keeping you abreast of our accomplishments going forward. Thank you.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.

Follow Fibrogen Inc (NASDAQ:FGEN)

Page 6 of 6